JP2024542592A5 - - Google Patents

Info

Publication number
JP2024542592A5
JP2024542592A5 JP2024531425A JP2024531425A JP2024542592A5 JP 2024542592 A5 JP2024542592 A5 JP 2024542592A5 JP 2024531425 A JP2024531425 A JP 2024531425A JP 2024531425 A JP2024531425 A JP 2024531425A JP 2024542592 A5 JP2024542592 A5 JP 2024542592A5
Authority
JP
Japan
Prior art keywords
alkylene
pharmaceutically acceptable
binding group
alkyl
compound according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024531425A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024542592A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2022/050952 external-priority patent/WO2023097038A1/en
Publication of JP2024542592A publication Critical patent/JP2024542592A/ja
Publication of JP2024542592A5 publication Critical patent/JP2024542592A5/ja
Pending legal-status Critical Current

Links

JP2024531425A 2021-11-26 2022-11-23 細胞表面受容体を標的とする開裂可能放射性リガンド及びその使用 Pending JP2024542592A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163283361P 2021-11-26 2021-11-26
US63/283,361 2021-11-26
PCT/US2022/050952 WO2023097038A1 (en) 2021-11-26 2022-11-23 Cleavable radioligands for targeting cell surface receptors and uses thereof

Publications (2)

Publication Number Publication Date
JP2024542592A JP2024542592A (ja) 2024-11-15
JP2024542592A5 true JP2024542592A5 (enExample) 2025-11-27

Family

ID=86540347

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024531425A Pending JP2024542592A (ja) 2021-11-26 2022-11-23 細胞表面受容体を標的とする開裂可能放射性リガンド及びその使用

Country Status (9)

Country Link
US (2) US12214059B2 (enExample)
EP (1) EP4436979A4 (enExample)
JP (1) JP2024542592A (enExample)
KR (1) KR20240121775A (enExample)
CN (1) CN118451091A (enExample)
CA (1) CA3238734A1 (enExample)
CL (1) CL2024001560A1 (enExample)
MX (1) MX2024005950A (enExample)
WO (1) WO2023097038A1 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018204872A2 (en) * 2017-05-05 2018-11-08 Fusion Pharmaceuticals Inc. Igf-1r monoclonal antibodies and uses thereof
EP4436979A4 (en) 2021-11-26 2026-06-10 Full Life Tech Uk Limited Cleftable radioligands for targeting cell surface receptors and their uses
WO2024126687A1 (en) * 2022-12-16 2024-06-20 Silence Therapeutics Gmbh Nucleic acids conjugated to an albumin binding moiety
EP4719486A1 (en) * 2023-05-31 2026-04-08 Full-Life Technologies UK Limited Conjugates and uses thereof
EP4719498A1 (en) * 2023-05-31 2026-04-08 Full-Life Technologies UK Limited Radioligands for targeting cell surface receptors and uses thereof
WO2025113628A1 (en) * 2023-11-30 2025-06-05 Full-Life Technologies Hk Limited Sstr receptor targeting radio compounds and uses thereof
CN118240015B (zh) * 2024-03-21 2025-03-21 中国科学院近代物理研究所 一种针对脑胶质瘤的靶向多肽及放射性示踪剂
WO2026002208A1 (zh) * 2024-06-28 2026-01-02 思路迪生物医药(上海)有限公司 前列腺特异性膜抗原小分子抑制剂及其放射性核素配合物的制备及应用
WO2026080432A1 (en) * 2024-10-07 2026-04-16 Beth Israel Deaconess Medical Center, Inc. Dimeric p-selectin inhibitors and uses thereof
CN121991166A (zh) * 2024-11-05 2026-05-08 成都纽瑞特医疗科技股份有限公司 放射性配体化合物及其用途
WO2026119233A1 (en) * 2024-12-04 2026-06-11 Full-Life Technologies Uk Limited Conjugates and uses thereof

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5021556A (en) 1987-07-22 1991-06-04 Neorx Corporation Method of radiolabeling chelating compounds comprising sulfur atoms with metal radionuclides
US5075099A (en) 1988-05-31 1991-12-24 Neorx Corporation Metal radionuclide chelating compounds for improved chelation kinetics
US5364613A (en) 1989-04-07 1994-11-15 Sieving Paul F Polychelants containing macrocyclic chelant moieties
US5367080A (en) 1990-11-08 1994-11-22 Sterling Winthrop Inc. Complexing agents and targeting radioactive immunoreagents useful in therapeutic and diagnostic imaging compositions and methods
US5886142A (en) 1997-05-20 1999-03-23 Thomas Jefferson University Radiolabeled thrombus imaging agents
US8575123B2 (en) * 2008-04-11 2013-11-05 Tekmira Pharmaceuticals Corporation Site-specific delivery of nucleic acids by combining targeting ligands with endosomolytic components
EP4420730A3 (en) 2009-03-19 2024-11-13 The Johns Hopkins University Psma-targeting compounds and uses thereof
ES2743482T3 (es) * 2014-05-06 2020-02-19 Univ Johns Hopkins Inhibidores de PSMA marcados con metal/radiometal para obtención de imágenes dirigidas a PSMA y radioterapia
MX392700B (es) 2016-08-10 2025-03-11 Cancer Targeted Tech Llc Inhibidores de antígeno de la membrana específico para la próstata (psma) quelados.
KR102724812B1 (ko) * 2017-04-05 2024-11-01 코넬 유니버시티 영상화 및 항종양 치료요법에 유용한 조정 가능한 약동학을 갖는 삼작용성 작제물
CA3060143A1 (en) * 2017-05-24 2018-11-29 Itm Isotopen Technologien Munchen Ag Novel psma-binding agents and uses thereof
AU2018352731B2 (en) 2017-10-22 2023-10-05 Provincial Health Services Authority Novel radiometal-binding compounds for diagnosis or treatment of prostate specific membrane antigen-expressing cancer
WO2019165200A1 (en) 2018-02-22 2019-08-29 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Chemical conjugates of evans blue derivatives and their use as radiotherapy and imaging agents for targeting prostate cancer
KR102156385B1 (ko) 2018-03-30 2020-09-15 (주)퓨쳐켐 전립선암 진단 및 치료를 위한 psma-표적 방사성의약품
WO2019246311A1 (en) 2018-06-19 2019-12-26 Lumiphore, Inc. Macrocycle conjugates
ES3038393T3 (en) * 2018-08-09 2025-10-13 Hoffmann La Roche Cleavable linker for peptide synthesis
US20200078478A1 (en) 2018-09-10 2020-03-12 Ming-Hsin Li Structural molecule of peptide derivative for PSMA-targeting radiotherapy diagnosis and treatment
KR20210116437A (ko) 2018-11-20 2021-09-27 코넬 유니버시티 방사성핵종의 마크로사이클릭 복합체 및 암의 방사선 요법에서의 이의 용도
WO2021046233A1 (en) 2019-09-03 2021-03-11 Cancer Targeted Technology Llc Chelate-containing psma inhibitors
WO2021163498A1 (en) 2020-02-14 2021-08-19 Northwestern University Retrograde neuronal tracers detectable by fluorescence and other imaging methods
TWI908773B (zh) * 2020-03-04 2025-12-21 日商日本醫事物理股份有限公司 化合物及放射性標誌化合物
JP7894086B2 (ja) 2020-05-06 2026-07-23 コーネル ユニヴァーシティー 銅含有セラグノスティック化合物及びその使用の方法
EP4436979A4 (en) 2021-11-26 2026-06-10 Full Life Tech Uk Limited Cleftable radioligands for targeting cell surface receptors and their uses

Similar Documents

Publication Publication Date Title
CA2526556C (en) Stable radiopharmaceutical compositions and methods for their preparation
US20250099632A1 (en) Cleavable radioligands for targeting cell surface receptors and uses thereof
CN108290924A (zh) 肽硫脲衍生物、含有其的放射性同位素标记化合物、和含有该化合物作为活性成分的用于治疗或诊断前列腺癌的药物组合物
JP2008266342A (ja) 部位特異的ターゲッティング用の放射性標識ペプチド組成物
JP7838149B2 (ja) 癌のイメージングおよび治療のための修飾されたｇｒｐｒアンタゴニストペプチド
JP2025506705A5 (enExample)
JP5557425B2 (ja) 改良ｎ４キレーターコンジュゲート
IL305134A (en) Dual mode radio and medical tracker
EP4631959A2 (en) Novel minigastrin-derived cholecystokinin 2 receptor binding molecules for imaging and targeted radiotherapy
US20120178906A1 (en) Chelation of metals to thiol groups using in situ reduction of disulfide-containing compounds by phosphines
US20260027244A1 (en) Silicon-based fluoride acceptor groups for radiopharmaceuticals
JP2024115570A (ja) 放射性核種標識薬剤
Floresta et al. RSC Medicinal Chemistry
TW202540073A (zh) 靶向ｓｓｔｒ受體的放射性化合物及其用途
WO2025162868A1 (en) Compounds comprising a silicon-based fluoride acceptor group useful as radiopharmceutical compounds
HK40077105B (en) Marking precursor with squaric acid coupling